The 36-month beta value for MYGN is also noteworthy at 1.90. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 6 rating it as “hold,” and 1 rating it as “sell.”
The public float for MYGN is 87.62M, and at present, short sellers hold a 3.87% of that float. The average trading volume of MYGN on December 20, 2024 was 864.46K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MYGN) stock’s latest price update
Myriad Genetics, Inc (NASDAQ: MYGN)’s stock price has dropped by -0.60 in relation to previous closing price of 13.25. Nevertheless, the company has seen a loss of -9.17% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
MYGN’s Market Performance
Myriad Genetics, Inc (MYGN) has seen a -9.17% fall in stock performance for the week, with a -12.20% decline in the past month and a -52.35% plunge in the past quarter. The volatility ratio for the week is 5.02%, and the volatility levels for the past 30 days are at 5.18% for MYGN. The simple moving average for the last 20 days is -13.38% for MYGN’s stock, with a simple moving average of -42.12% for the last 200 days.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with UBS repeating the rating for MYGN by listing it as a “Neutral.” The predicted price for MYGN in the upcoming period, according to UBS is $18 based on the research report published on December 10, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $21, previously predicting the price at $30. The rating they have provided for MYGN stocks is “Market Perform” according to the report published on December 09th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to MYGN, setting the target price at $32 in the report published on September 19th of the current year.
MYGN Trading at -27.04% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.05% of loss for the given period.
Volatility was left at 5.18%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares sank -13.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.96% lower at present.
During the last 5 trading sessions, MYGN fell by -9.17%, which changed the moving average for the period of 200-days by -42.59% in comparison to the 20-day moving average, which settled at $15.20. In addition, Myriad Genetics, Inc saw -31.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from DIAZ PAUL J, who sale 15,000 shares at the price of $22.93 back on Oct 11 ’24. After this action, DIAZ PAUL J now owns 962,378 shares of Myriad Genetics, Inc, valued at $343,950 using the latest closing price.
DIAZ PAUL J, the Officer of Myriad Genetics, Inc, proposed sale 15,000 shares at $22.93 during a trade that took place back on Oct 11 ’24, which means that DIAZ PAUL J is holding shares at $343,950 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc stands at -0.14. The total capital return value is set at -0.12. Equity return is now at value -16.39, with -10.40 for asset returns.
Based on Myriad Genetics, Inc (MYGN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -1.79. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -38.6.
Currently, EBITDA for the company is -186.1 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 1.51. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
In summary, Myriad Genetics, Inc (MYGN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
